Alexion Pharmaceuticals Inc.Find Ratings Reports
ALEXION PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.31 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 2.29% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||910.1||830.74|
|Net Income ($mil)||30.3||92.44|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||1474.1||1293.0|
|Total Assets ($mil)||13583.3||13253.0|
|Total Debt ($mil)||3231.0||3288.0|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||43.86||94.73|
|Return on Assets||3.26||3.01|
|Return on Equity||4.98||4.58|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||222.3||224.0|
|Div / share||0.0||0.0|
|Book value / share||40.0||38.81|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1972333.0||2044604.0|
HOLD. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 46.41 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.58. To use another comparison, its price-to-book ratio of 3.00 indicates valuation on par with the S&P 500 average of 3.27 and a significant discount versus the industry average of 20.74. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ALXN 61.23||Peers 46.41||ALXN 23.91||Peers 24.87|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ALXN is trading at a significant premium to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALXN is trading at a valuation on par to its peers.
|ALXN 14.37||Peers 17.63||ALXN 0.25||Peers 0.37|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
ALXN is trading at a valuation on par with its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ALXN trades at a significant discount to its peers.
|ALXN 3.00||Peers 20.74||ALXN 10.73||Peers 0.49|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALXN is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ALXN is expected to have an earnings growth rate that significantly exceeds its peers.
|ALXN 7.51||Peers 83.14||ALXN 15.14||Peers 469.60|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALXN is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALXN significantly trails its peers on the basis of sales growth